Our results showed that MPV level was higher in the pregnant than the control group. However, MPV did not differ both between mild and severe preeclampsia, and preeclampsia and non-preeclamptic pregnant women.

IntroductionAcute pancreatitis (AP) is the third most common gastrointestinal disease at hospital admission. The etiology and pathogenesis of this disease are not completely clear. Our study was intended to determine the systemic levels of pentraxin-3 (PTX-3), myeloperoxidase (MPO), procalcitonin (PCT), and C-reactive protein (CRP) as prognostic parameters in early stages of AP. We also determined the effects of treatment on PTX-3, MPO, PCT and CRP levels in AP.Material and methodsThe study group comprised 44 AP patients (22 male, 22 female; age: 49.3 ±16.9 years) referred to our outpatient clinic. Additionally, our investigation included a control group of 30 healthy volunteers (18 male, 12 female; age: 50.8 ±12.6 years).ResultsLeukocytes, glucose, aspartate aminotransferase (AST (SGOT)), alanine aminotransferase (ALT (SGPT)), alkaline phosphatase (ALP), total and direct bilirubin levels were significantly higher in the AP group (p < 0.05, all). CRP, PTX-3, MPO and PCT were considerably higher in the AP group (p < 0.001, all), and after treatment, CRP, PTX-3, MPO and PCT levels were significantly lower (p < 0.001, all).ConclusionsOur findings indicated that the CRP, PTX-3, MPO and PCT levels increase in patients with AP and hence these indicators can be used as diagnostic factors to predict inflammation severity in AP. It was revealed that after treatment, there were significant reductions in biomarker levels. However, further research is needed in order to understand how these biomarkers can help to monitor inflammatory responses in AP.

Elevated plasma resistin, apelin, chemerin, and visfatin levels in morbidly obese patients are gradually reduced after weight loss. According to these findings, LAGB surgery is found to be an important and efficient means for morbidly obese patients both to lose weight and to develop a better metabolic risk profile in a short time period.

No abstract

The requirement for diagnostic surgical operations of gastrointestinal systemdiseases significantly decreases with the help of proper diagnostic tools. Thesemodalities are also beneficial for identifying postoperative complications, allowing usto diagnose them in earlier stages, and increasing the postoperative survival rates.Biomarkers are considered an integral part of diagnostic examinations. Developmentsof biomarkers used for diagnosing and treating abdominal diseases are essential forimproving our capabilities in non-invasive monitoring. In this chapter, we review boththe novel and the routine biomarkers in the diagnosis and follow-up of gastrointestinalsystem diseases.